Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Granneman

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Antiviral Research|October 1, 1998
Recent developments in HIV protease inhibitor therapyA Molla, G R Granneman, E Sun, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 30, 1998
Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteersS L Wong, G Cao, R Mack, et al.
Journal of Clinical Pharmacology|March 20, 1998
The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteersS L Wong, G Cao, R J Mack, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1991
Pharmacokinetics of temafloxacin in humans after single oral dosesG R Granneman, P Carpentier, P J Morrison, et al.
Clinical Pharmacokinetics|January 1, 1992
Effect of antacid medication on the pharmacokinetics of temafloxacinG R Granneman, U Stephan, B Birner, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
Pharmacokinetics of sertindole in healthy young and elderly male and female subjectsS L Wong, G Cao, R J Mack, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1992
Pharmacokinetics of temafloxacin in humans after multiple oral dosesG R Granneman, P Carpentier, P J Morrison, et al.
British Journal of Clinical Pharmacology|October 1, 1993
Stereoselective pharmacokinetics of pazinaclone, a new non-benzodiazepine anxiolytic, and its active metabolite in healthy subjectsZ Hussein, D J Mulford, B A Bopp, et al.
Journal of Cardiovascular Pharmacology|May 1, 1993
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failureS K Gupta, G R Granneman, M Packer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1993
Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogsZ Hussein, D J Mulford, B A Bopp, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Antiviral Research|October 1, 1998
Recent developments in HIV protease inhibitor therapyA Molla, G R Granneman, E Sun, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 30, 1998
Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteersS L Wong, G Cao, R Mack, et al.
Journal of Clinical Pharmacology|March 20, 1998
The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteersS L Wong, G Cao, R J Mack, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1991
Pharmacokinetics of temafloxacin in humans after single oral dosesG R Granneman, P Carpentier, P J Morrison, et al.
Clinical Pharmacokinetics|January 1, 1992
Effect of antacid medication on the pharmacokinetics of temafloxacinG R Granneman, U Stephan, B Birner, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
Pharmacokinetics of sertindole in healthy young and elderly male and female subjectsS L Wong, G Cao, R J Mack, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1992
Pharmacokinetics of temafloxacin in humans after multiple oral dosesG R Granneman, P Carpentier, P J Morrison, et al.
British Journal of Clinical Pharmacology|October 1, 1993
Stereoselective pharmacokinetics of pazinaclone, a new non-benzodiazepine anxiolytic, and its active metabolite in healthy subjectsZ Hussein, D J Mulford, B A Bopp, et al.
Journal of Cardiovascular Pharmacology|May 1, 1993
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failureS K Gupta, G R Granneman, M Packer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1993
Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogsZ Hussein, D J Mulford, B A Bopp, et al.
Pageof 9